BioVentrix has unveiled its Remote Ventricular Reduction (RVR), being developed to downsize the enlarged left ventricle in patients with heart failure.

At the Transcatheter Cardiovascular Therapeutics conference, held in Washington, D.C. last month, results of the initial RVR studies in sheep were presented. In the cases, the procedure improved the heart's pumping ability, decreased muscle wall tension and created a more normal-sized heart, which up until now has taken open heart surgery to achieve, according to the San Ramon, Calif.-based company.